Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


COX-2 Inhibitors Significantly Reduce Risk of Cancer


Results from a new, five-year study show that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers.

The study findings were released today at the annual meeting of the American Association for Cancer Research in Washington, D.C.
Randall E. Harris, M.D., Ph.D.

“We believe this is the first study to show that selective COX-2 inhibitors have significant chemopreventive effects against breast cancer,” says Dr. Randall Harris, professor and director of the Center for Molecular Epidemiology and Environmental Health in The Ohio State University College of Medicine and lead author of the study.

The results come from a larger, case-control study of NSAID use and its impact upon the four leading types of cancer in the United States: breast, lung, prostate and colon cancer. NSAIDs are non-steroidal, anti-inflammatory drugs that block the COX-2 enzyme pathway that is often activated in inflammation, cancer, heart disease and other disorders.

Harris and his colleagues studied the use of celecoxib (Celebrex), rofecoxib (Vioxx), regular aspirin, low-dose aspirin, ibuprofen and acetaminophen among 323 women with breast cancer from 1999-2004.

They compared the results with those from a control group of 649 cancer-free women matched for age, race and county of residence.

They discovered that women who used NSAIDs on a regular basis had less breast cancer. Specifically, they found that those who used celecoxib or rofecoxib for at least two years appeared to benefit the most, experiencing a 71 percent reduction in risk of breast cancer. Ibuprofen use over the same period was associated with a 64 percent reduction, while regular aspirin offered a 51 percent reduction in risk of the disease.

On the other hand, acetaminophen, which has a negligible effect upon COX-2 activity, and low-dose aspirin provided no significant change in the risk of breast cancer.

“The COX-2 signaling pathway is important in cancer because when it’s activated, it can stimulate many key steps in cancer development, including cell division, inhibition of cell death, angiogenesis (the creation of new blood vessels to nourish growing tumors) and metastasis,” says Harris, who is also a member of the OSU Comprehensive Cancer Center.

Harris says his research group is only midway through analyzing data from the other parts of the study, but adds that early results suggest that regular use of selective COX-2 inhibitors appears to provide about the same magnitude of protection from prostate, lung and colon cancer.

“These results suggest strong potential for regular use of these drugs in cancer prevention. Still, we know these drugs may have side effects, so we are not advising people to go out and start taking them until more studies confirm that they are safe and effective,” says Harris.

Celebrex is still widely used for pain relief, but Vioxx was pulled off the market in 2004 following reports of heightened risk of heart attacks.

“It’s clear that we need to have multiple retrospective and prospective studies to validate these findings,” says Harris, who has been studying the impact of COX-2 inhibitors for many years. “Eventually, we may find that regular intake of a low dose of a COX-2 inhibitor may be enough to reset the COX-2 cascade and safely protect people against cancer.”

Grants from Pfizer and the National Cancer Institute supported the study.

Study co-authors include Joanne Beebe-Donk and Galal Alshafie, both colleagues in the Center for Molecular Epidemiology and Environmental Health in the OSU College of Medicine.

Michelle Gailiun | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung

nachricht High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>